Pharmaceutical companies are entering into partnerships and acquisitions with technology firms to use artificial intelligence in drug development[1]. Eli Lilly partners with Nvidia and AstraZeneca acquires Boston-based Modella AI[1]. The acquisition of Modella AI is used for the development of drugs against oncological diseases using AI, which analyzes large volumes of data[1]. AstraZeneca's collaboration with Modella AI has been ongoing since July last year, and the acquisition price has not been disclosed[1]. AI accelerates drug development by selecting promising candidates from vast data, reducing costs and shortening time from laboratory to clinical trials[3]. In clinical trials, AI helps design protocols, select patients and predict outcomes[3]. These strategies are intended to streamline the development of innovative medicines in the context of patent challenges[1][3].